Reported 1 day ago
Novo Nordisk has revised its financial outlook downward due to slowing demand for its GLP-1 weight loss and diabetes treatments, Wegovy and Ozempic. The company's third-quarter profits and revenues fell short of analyst expectations, reflecting increased competition and pricing pressures in the weight-loss drug market. This marks the fourth time the company has adjusted its guidance in 2025, with U.S. shares dropping approximately 46% this year.
Source: YAHOO